<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> (TOR) kinase is part of an evolutionarily conserved signaling pathway that coordinates cell growth, survival, and autophagy </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, pharmacological studies using <z:chebi fb="0" ids="9168">rapamycin</z:chebi> have suggested a cardioprotective effect of TOR signaling inhibition on <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We found that <z:chebi fb="0" ids="9168">rapamycin</z:chebi> exerts a conserved cardioprotective effect in two adult zebrafish models of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> of different etiology, and provided the first genetic evidence to support a long-term cardioprotective effect of TOR signaling inhibition </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, we detected dynamic TOR-autophagy activities along different stages of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>This needs to be considered when developing TOR-autophagy-based therapeutics for <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
</text></document>